modelBosutinib

Diagram of Bosutinib

Extends from Pharmacolibrary.Drugs.ATC.L.L01EA04.

Information

name:Bosutinib
ATC code:L01EA04
route:oral
compartments:2
dosage:500mg
volume of distribution:223L
clearance:63.6L/h
other parameters in model implementation

Bosutinib is an oral tyrosine kinase inhibitor used primarily for the treatment of chronic myelogenous leukemia (CML) in adults. It is approved and utilized as a targeted therapy in patients who are resistant or intolerant to prior therapy.

Pharmacokinetics

Pharmacokinetic parameters are reported for adult patients with chronic phase chronic myelogenous leukemia after oral administration of bosutinib.

References

  1. Abbas, R, & Hsyu, PH (2016). Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clinical pharmacokinetics 55(10) 1191–1204. DOI:10.1007/s40262-016-0391-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27113346

  2. Hsyu, PH, et al., & Amantea, M (2014). Population pharmacokinetic and pharmacodynamic analysis of bosutinib. Drug metabolism and pharmacokinetics 29(6) 441–448. DOI:10.2133/dmpk.DMPK-13-RG-126 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24919837

  3. Abbas, R, et al., & Sonnichsen, D (2012). Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clinical therapeutics 34(9) 2011–9.e1. DOI:10.1016/j.clinthera.2012.07.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884766

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)